Review for "Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24‐week, multicentre, randomised, double‐blind, placebo‐controlled, phase III trial"

v1

Review for "Efficacy and safety of enavogliflozin, a novel <scp>SGLT2</scp> inhibitor, in Korean people with type 2 diabetes: a 24‐week, multicentre, randomised, double‐blind, placebo‐controlled, phase <scp>III</scp> trial"

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/02CF7CDF.svg?ark=w1%2F20260521%2F02CF7CDF&value=id)](https://nobleid.org/work/w1/20260521/02CF7CDF)

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors